Remicade Labeling Should Allow For Higher Dose Option, Arthritis Cmte. Says
Centocor Remicade labeling should indicate that some patients may benefit from a higher dosage of the drug, but should also emphasize the greater safety risks associated with higher dosing, members of the FDA Arthritis Drugs Advisory Committee suggested.
You may also be interested in...
A Centocor analysis comparing Medicare costs for Remicade to Immunex' Enbrel relies on an assumption that physicians would use the low dose of Remicade.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011